Entera Bio Ltd.
ENTXHealthcare|Biotechnology|IL
$3.14
+0.15 (+5.02%)
DCF Value
$0.14
Tangible Book / Share
$1.89
Graham Number
$0.72
Cash / Share
$1.83
Financials
Financial Snapshot
Market Cap
$546.1M
Enterprise Value
$280.6M
Revenue (TTM)
$0.00
Net Income (TTM)
$1.8M
Cash & Investments
$265.9M
Net Cash
$265.5M
Free Cash Flow (TTM)
-$54.9K
Operating CF (TTM)
-$1.0K
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$265.9M
Quarterly Burn
$261.00
Monthly Burn
$87.00
Est. Runway
~1018708.8 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.2M | $11.7M | $11.5M | $15.2M | $8.6M | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M | $265.9M | |
| Operating Cash Flow | -$3.1M | -$4.5M | -$9.8M | -$8.9M | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.4M | -$1.0K | |
| Free Cash Flow | -$3.2M | -$4.6M | -$9.9M | -$9.0M | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M | -$54.9K | |
| Capital Expenditure | -$41.0K | -$51.0K | -$68.0K | -$40.0K | -$53.0K | -$17.0K | -$47.0K | -$17.0K | -$3.0K | -$107.0K | -$53.8K | |
| Financing Cash Flow | $7.2M | $11.1M | $9.6M | $12.7M | $4.1M | $25.4M | $13.0K | $6.0M | $4.5M | $13.7M | $271.9M |
R&D Spending
R&D (TTM)
$12.1M
R&D Intensity
—
R&D Growth vs Prior
+101.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $500.0K | $236.0K | $365.0K | $571.0K | $134.0K | $0.00 | $181.0K | $42.0K | $0.00 | |
| R&D Expense | $2.6M | $2.8M | $8.5M | $7.0M | $6.4M | $6.8M | $5.8M | $4.5M | $4.5M | $6.0M | $12.1M | |
| R&D % of Revenue | — | — | 1703.6% | 2949.6% | 1748.5% | 1185.8% | 4316.4% | — | 2485.6% | 14295.2% | — | |
| SG&A | $2.7M | $8.6M | $2.8M | $4.3M | $4.9M | $5.7M | $7.3M | $4.4M | $5.1M | $5.5M | $6.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $500.0K | $236.0K | $365.0K | $571.0K | $134.0K | $0.00 | $181.0K | $42.0K | $0.00 | |
| Cost of Revenue | $35.0K | $43.0K | $0.00 | $448.0K | $300.0K | $373.0K | $165.0K | $56.0K | $172.0K | $42.0K | $7.0K | |
| Gross Profit | -$35.0K | -$43.0K | $500.0K | -$212.0K | $65.0K | $198.0K | -$31.0K | -$56.0K | $9.0K | $0.00 | -$7.0K | |
| R&D | $2.6M | $2.8M | $8.5M | $7.0M | $6.4M | $6.8M | $5.8M | $4.5M | $4.5M | $6.0M | $12.1M | |
| SG&A | $2.7M | $8.6M | $2.8M | $4.3M | $4.9M | $5.7M | $7.3M | $4.4M | $5.1M | $5.5M | $6.3M | |
| Operating Income | -$5.4M | $11.3M | -$10.9M | -$11.5M | -$11.2M | -$12.2M | -$13.1M | -$8.9M | -$9.6M | -$11.5M | -$11.1M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $84.0K | $28.0K | $29.0K | $0.00 | $0.00 | $0.00 | $0.00 | $2.7M | |
| Pretax Income | -$1.2M | -$11.2M | -$10.3M | -$10.8M | -$11.2M | -$12.2M | -$12.9M | -$8.9M | -$9.5M | -$11.4M | $1.8M | |
| Net Income | -$1.2M | -$11.2M | -$10.3M | -$10.8M | -$11.2M | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M | $1.8M | |
| EPS (Diluted) | -0.10 | -0.94 | -1.29 | -0.90 | -0.54 | -0.47 | -0.45 | -0.31 | -0.25 | -0.25 | -0.17 | |
| EBITDA | -$5.3M | -$11.0M | -$10.8M | -$10.5M | -$11.1M | -$12.2M | -$12.9M | -$8.8M | -$9.5M | -$11.4M | -$11.1M | |
| Shares Out. (M) | 11.90 | 11.90 | 11.51 | 12.15 | 18.42 | 26.13 | 28.81 | 29.01 | 37.65 | 46.19 | 145.08 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $11.7M | $7.5M | $15.2M | $8.6M | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M | $265.9M | |
| Short-Term Investments | $0.00 | $0.00 | $4.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $5.4M | $12.4M | $12.5M | $15.6M | $9.1M | $25.3M | $12.8M | $11.3M | $9.0M | $7.1M | $276.5M | |
| Total Assets | $6.3M | $13.3M | $13.3M | $16.7M | $9.7M | $26.0M | $13.1M | $11.8M | $9.4M | $16.0M | $277.0M | |
| Total Current Liabilities | $10.5M | $2.0M | $1.8M | $4.6M | $1.8M | $3.2M | $1.3M | $1.1M | $1.2M | $2.2M | $2.2M | |
| Long-Term Debt | $15.9M | $3.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $260.0K | $190.0K | |
| Total Liabilities | $31.5M | $44.8M | $3.2M | $4.8M | $2.2M | $3.4M | $1.4M | $1.4M | $1.3M | $2.9M | $2.8M | |
| Stockholders' Equity | -$25.2M | -$31.6M | $10.1M | $11.9M | $7.5M | $22.6M | $11.8M | $10.4M | $8.1M | $13.1M | $274.3M | |
| Retained Earnings | -$30.6M | -$41.8M | -$52.1M | -$62.9M | -$70.2M | -$82.4M | -$95.5M | -$104.4M | -$113.9M | -$125.4M | -$151.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M | -$4.5M | -$9.8M | -$8.9M | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.4M | -$1.0K | |
| Capital Expenditure | -$41.0K | -$51.0K | -$68.0K | -$40.0K | -$53.0K | -$17.0K | -$47.0K | -$17.0K | -$3.0K | -$107.0K | -$53.8K | |
| Free Cash Flow | -$3.2M | -$4.6M | -$9.9M | -$9.0M | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M | -$54.9K | |
| Investing Cash Flow | -$1.1M | $1.0M | -$4.1M | $3.9M | -$53.0K | -$17.0K | -$102.0K | -$17.0K | -$3.0K | -$107.0K | -$53.8K | |
| Financing Cash Flow | $7.2M | $11.1M | $9.6M | $12.7M | $4.1M | $25.4M | $13.0K | $6.0M | $4.5M | $13.7M | $271.9M | |
| Issuance of Stock | $0.00 | $12.1M | $9.6M | $12.5M | $4.0M | $21.8M | $13.0K | $6.6M | $4.0M | $13.7M | $387.4K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $7.2M | -$980.0K | $0.00 | -$114.0K | -$136.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.5M | $4.9M | $1.2M | $1.5M | $901.0K | $1.9M | $2.2M | $1.7M | $2.6M | $2.8M | $3.1M | |
| Net Change in Cash | $3.0M | $7.6M | -$4.2M | $7.7M | -$6.6M | $16.3M | -$12.6M | -$1.3M | -$2.3M | $6.2M | $255.8M |
Dilution Tracker
Shares outstanding grew 150.8% over 5 years — significant dilution
Shares Outstanding
174M
5-Year Share Growth
+150.8%
Stock Issuance (TTM)
$387.4K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 11.90 | 11.90 | 11.51 | 12.15 | 18.42 | 26.13 | 28.81 | 29.01 | 37.65 | 46.19 | 145.08 | |
| Change vs Prior % | — | 0.0% | -3.3% | 5.5% | 51.6% | 41.9% | 10.2% | 0.7% | 29.8% | 22.7% | 214.1% | |
| Stock Issuance | $0.00 | $12.1M | $9.6M | $12.5M | $4.0M | $21.8M | $13.0K | $6.6M | $4.0M | $13.7M | $387.4K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.5M | $4.9M | $1.2M | $1.5M | $901.0K | $1.9M | $2.2M | $1.7M | $2.6M | $2.8M | $3.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 100.0% | -89.8% | 17.8% | 34.7% | -23.1% | — | 5.0% | 0.0% | — | |
| Operating Margin % | — | — | -2172.2% | -4853.4% | -3059.7% | -2139.6% | -9752.2% | — | -5295.6% | -27450.0% | — | |
| Net Margin % | — | — | -2060.8% | -4574.2% | -3072.9% | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% | — | |
| EBITDA Margin % | — | — | -2161.4% | -4437.7% | -3042.5% | -2130.3% | -9604.5% | — | -5238.1% | -27164.3% | — | |
| FCF Margin % | — | — | -1972.8% | -3796.2% | -2906.8% | -1590.2% | -9362.7% | — | -3768.5% | -17802.4% | — | |
| ROE % | 4.7% | 35.5% | -101.9% | -90.6% | -149.3% | -54.0% | -111.2% | -85.6% | -118.1% | -87.3% | 2.3% | |
| ROA % | -19.1% | -84.3% | -77.2% | -64.6% | -115.4% | -46.9% | -99.6% | -75.6% | -101.6% | -71.5% | 0.6% | |
| ROIC % | -95.3% | 99.4% | -94.0% | -93.2% | -138.4% | -52.8% | -110.0% | -82.7% | -114.3% | -218.8% | -4.1% | |
| R&D / Revenue % | — | — | 1703.6% | 2949.6% | 1748.5% | 1185.8% | 4316.4% | — | 2485.6% | 14295.2% | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | -52.8% | 54.7% | 56.4% | -76.5% | -100.0% | 0.0% | -76.8% | |
| Gross Profit | -25.0% | -22.9% | 1262.8% | -142.4% | 130.7% | 204.6% | -115.7% | -80.6% | 116.1% | -100.0% | |
| Operating Income | -45.0% | 311.3% | -195.8% | -5.5% | 2.5% | -9.4% | -7.0% | 31.6% | -7.2% | -20.3% | |
| Net Income | 72.0% | -833.9% | 8.0% | -4.8% | -3.9% | -8.7% | -7.3% | 32.0% | -7.3% | -19.9% | |
| EPS (Diluted) | 72.2% | -840.0% | -37.2% | 30.2% | 40.0% | 13.0% | 4.3% | 31.1% | 19.4% | 0.0% | |
| Operating Cash Flow | 10.1% | -44.0% | -116.4% | 9.0% | -18.4% | 14.2% | -37.9% | 41.5% | 6.7% | -8.1% | |
| Free Cash Flow | 10.3% | -43.8% | -115.5% | 9.2% | -18.4% | 14.4% | -38.2% | 41.6% | 6.9% | -9.6% | |
| R&D Expense | 25.2% | 4.5% | 207.7% | -18.3% | -8.3% | 6.1% | -14.6% | -23.0% | 1.0% | 33.5% | |
| SG&A Expense | 71.4% | 215.4% | -66.8% | 50.6% | 13.3% | 17.3% | 27.5% | -38.9% | 15.0% | 8.4% | |
| Total Assets | 128.8% | 111.2% | 0.5% | 25.2% | -41.8% | 167.3% | -49.5% | -10.4% | -20.2% | 70.3% | |
| Book Value / Share | -36.4% | -25.0% | 124.2% | 10.3% | -58.4% | 111.7% | -52.7% | -12.2% | -40.1% | 32.2% | |
| Debt | 82.8% | -73.6% | -100.0% | 0.0% | 44.5% | -30.1% | -69.9% | 328.6% | -30.3% | 80.1% | |
| Diluted Shares | 0.0% | 0.0% | -3.3% | 5.5% | 51.6% | 41.9% | 10.2% | 0.7% | 29.8% | 22.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High54.49 / 129.07 / 2133.59
P/B1.66
10Y Low / Med / High1.68 / 3.27 / 9.88
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High32.14 / 65.76 / 1976.02
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.14
Tangible Book / Share
$1.89
Net Current Assets / Share
$1.57
Graham Number
$0.72
Graham Net-Net
$1.81
Cash / Share
$1.83
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -44.86 | -4.79 | -3.35 | -2.38 | -2.00 | -6.00 | -1.62 | -1.94 | -8.48 | -7.76 | -18.61 | |
| P/S Ratio | 0.00 | 0.00 | 69.38 | 110.14 | 54.49 | 129.07 | 156.94 | 0.00 | 440.99 | 2133.59 | 0.00 | |
| P/B Ratio | -2.13 | -1.71 | 3.43 | 2.18 | 2.65 | 3.27 | 1.79 | 1.68 | 9.88 | 6.84 | 1.66 | |
| EV/EBITDA | -12.08 | -4.16 | -2.52 | -1.06 | -1.06 | -4.04 | -0.68 | -0.77 | -7.53 | -7.27 | -25.37 | |
| EV/Revenue | 0.00 | 0.00 | 54.36 | 46.91 | 32.14 | 86.00 | 65.76 | 0.00 | 394.64 | 1976.02 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
119.10
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $54.6M | $5.6K | $2.1K |
| Net Income | -$19.3M | -$17.7M | -$18.6M |
| EPS | $-0.42 | $-0.38 | $-0.40 |
| # Analysts (EPS) | 3 | 3 | 4 |